Abzena picks North Car­oli­na as the home for its 6th man­u­fac­tur­ing site, plans to add 325 jobs in San­ford

While Boston and San Fran­cis­co are the un­ques­tioned lead­ing biotech hubs in the US, drug­mak­ers — par­tic­u­lar­ly con­tract man­u­fac­tur­ers — are look­ing else­where for cheap­er re­al es­tate and un­tapped po­ten­tial. Now, a San Diego-based bi­o­log­ics mak­er look­ing to rapid­ly scale up is set­ting down roots in North Car­oli­na.

CD­MO Abzena will add 325 jobs in San­ford, NC, as part of a $200 mil­lion bi­o­log­ics plant that will even­tu­al­ly house around 24,000 square feet of biore­ac­tor ca­pac­i­ty, the com­pa­ny said.

The fa­cil­i­ty is com­ing as part of a mul­ti-phase out­lay that will add four mod­u­lar suites in the ini­tial phase, each of which will house two 2,000-liter biore­ac­tors. A sec­ond phase will add an­oth­er two suites with the 2,000-liter biore­ac­tors, for a to­tal of 12. The fa­cil­i­ty, Abzena said, will ac­com­mo­date Phase III and com­mer­cial man­u­fac­tur­ing, and will al­so be equipped to han­dle con­tin­u­ous man­u­fac­tur­ing and per­fu­sion by the mid­dle of 2022.

Kim­ball Hall

The ex­pan­sion al­so comes as a big boon for North Car­oli­na, one of the fastest-grow­ing biotech hubs in the coun­try.

“North Car­oli­na of­fers great re­sources for ac­cess to a tal­ent­ed work­force and oth­er re­sources for us as we bring the new fa­cil­i­ty on-line,” Abzena Pres­i­dent and COO Kim­ball Hall said in a state­ment.

The Abzena an­nounce­ment comes just weeks af­ter CD­MO Fu­ji­film Diosynth Biotech­nolo­gies al­so picked North Car­oli­na as the fu­ture home of its own $2 bil­lion bi­o­log­ics site that will ri­val some of the largest fa­cil­i­ties in the world. The Japan­ese sub­sidiary picked Hol­ly Springs, NC, for its cell cul­ture, plan­ning to add 725 jobs in the area by 2028.

Fu­ji­film had been search­ing for a home for the plant af­ter an­nounc­ing its in­tent to build back in Jan­u­ary. The com­pa­ny eyed lo­ca­tions with­in shout­ing dis­tance of its ex­ist­ing US sites in Col­lege Sta­tion, TX, and Mor­risville, NC. Ul­ti­mate­ly, North Car­oli­na won the lot­tery due to its “strong pool of tech­ni­cal tal­ent, lo­cal re­sources and part­ners with the right com­pe­ten­cies, clean en­er­gy re­sources, and sus­tain­abil­i­ty for fu­ture growth,” Fu­ji­film said in a re­lease.

The plants will come on­line in spring 2025 and house eight 20,000-liter biore­ac­tors with the po­ten­tial to ex­pand and add a fur­ther 24 biore­ac­tors of the same size “based on mar­ket de­mand,” the com­pa­ny says. The site will al­so in­clude com­mer­cial-scale, au­to­mat­ed fill-fin­ish and as­sem­bly, pack­ag­ing and la­bel­ing ser­vices.

So­cial im­age: Jonathan Gold­man, Abzena CEO

Biotech Half­time Re­port: Af­ter a bumpy year, is biotech ready to re­bound?

The biotech sector has come down firmly from the highs of February as negative sentiment takes hold. The sector had a major boost of optimism from the success of the COVID-19 vaccines, making investors keenly aware of the potential of biopharma R&D engines. But from early this year, clinical trial, regulatory and access setbacks have reminded investors of the sector’s inherent risks.

RBC Capital Markets recently surveyed investors to take the temperature of the market, a mix of specialists/generalists and long-only/ long-short investment strategies. Heading into the second half of the year, investors mostly see the sector as undervalued (49%), a large change from the first half of the year when only 20% rated it as undervalued. Around 41% of investors now believe that biotech will underperform the S&P500 in the second half of 2021. Despite that view, 54% plan to maintain their position in the market and 41% still plan to increase their holdings.

Covid-19 vac­cine boost­ers earn big thumbs up, but Mod­er­na draws ire over world sup­ply; What's next for Mer­ck’s Covid pill?; The C-suite view on biotech; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

You may remember that at the beginning of this year, Endpoints News set a goal to go broader and deeper. We are still working towards that, and are excited to share that Beth Snyder Bulik will be joining us on Monday to cover all things pharma marketing. You can sign up for her weekly Endpoints MarketingRx newsletter in your reader profile.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 119,700+ biopharma pros reading Endpoints daily — and it's free.

No­var­tis de­vel­op­ment chief John Tsai: 'We go deep in the new plat­form­s'

During our recent European Biopharma Summit, I talked with Novartis development chief John Tsai about his experiences over the 3-plus years he’s been at the pharma giant. You can read the transcript below or listen to the exchange in the link above.

John Carroll: I followed your career for quite some time. You’ve had more than 20 years in big pharma R&D and you’ve obviously seen quite a lot. I really was curious about what it was like for you three and a half years ago when you took over as R&D chief at Novartis. Obviously a big move, a lot of changes. You went to work for the former R&D chief of Novartis, Vas Narasimhan, who had his own track record there. So what was the biggest adjustment when you went into this position?

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Roche's Tecen­triq cross­es the fin­ish line first in ad­ju­vant lung can­cer, po­ten­tial­ly kick­ing off gold rush

While falling behind the biggest PD-(L)1 drugs in terms of sales, Roche has looked to carve out a space for its Tecentriq with a growing expertise in lung cancer. The drug will now take an early lead in the sought-after adjuvant setting — but competitors are on the way.

The FDA on Friday approved Tecentriq as an adjuvant therapy for patients with Stage II-IIIA non small cell lung cancer with PD-(L)1 scores greater than or equal to 1, making it the first drug of its kind approved in an early setting that covers around 40% of all NSCLC patients.

Amit Etkin, Alto Neuroscience CEO (Alto via Vimeo)

A star Stan­ford pro­fes­sor leaves his lab for a start­up out to re­make psy­chi­a­try

About five years ago, Amit Etkin had a breakthrough.

The Stanford neurologist, a soft-spoken demi-prodigy who became a professor while still a resident, had been obsessed for a decade with how to better define psychiatric disorders. Drugs for depression or bipolar disorder didn’t work for many patients with the conditions, and he suspected the reason was how traditional diagnoses didn’t actually get at the heart of what was going on in a patient’s brain.

Susan Galbraith, Executive VP, Oncology R&D, AstraZeneca

As­traZeneca on­col­o­gy R&D chief Su­san Gal­braith: 'Y­ou're go­ing to need or­thog­o­nal com­bi­na­tion­s'

 

Earlier in the week we broadcast our 4th annual European Biopharma Summit with a great lineup of top execs. One of the one-on-one conversations I set up was with Susan Galbraith, the oncology research chief at AstraZeneca. In a wide-ranging discussion, Galbraith reviewed the cancer drug pipeline and key trends influencing development work at the pharma giant. You can watch the video, above, or stick with the script below. — JC

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Rahul Singhvi, Resilience CEO

A Bob Nelsen start­up turns to Har­vard to help sharp­en its tech, in­spir­ing first spin­out

One of Bob Nelsen’s latest projects is headed to Harvard.

Resilience, a company started with the goal of establishing itself as a “one-stop-shop” for companies looking to scale manufacturing, including for hard-to-develop cell and gene therapies, is less than a year old. Friday, it announced a five-year R&D deal with Harvard University that includes $30 million to develop biologics, including vaccines, nucleic acids and cell and gene therapies.

Tillman Gerngross, Adagio CEO

Q&A: Till­man Gern­gross ex­plains why his Covid mAb will have an edge over an al­ready crowd­ed field

If anyone knows about monoclonal antibodies, it’s serial entrepreneur, Adimab CEO, and Dartmouth professor of bioengineering Tillman Gerngross.

Even the name of Gerngross’ new antibody startup Adagio Therapeutics is meant to reflect his vision behind the development of his Covid-19 mAb: slowly, he said, explaining that “everyone else, whether it’s Regeneron, Lilly, or AstraZeneca, Vir, they all valued speed over everything.”

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Susan Galbraith speaking at Endpoints News' virtual EUBIO21 summit

Imfinzi/treme­li­mum­ab com­bo scores As­traZeneca an­oth­er OS win — this time in liv­er can­cer

Is the tide turning on AstraZeneca’s battered PD-L1/CTLA4 combo?

A single priming dose of the experimental tremelimumab, followed by Imfinzi every four weeks, beat Nexavar (sorafenib) in helping a group of liver cancer patients live longer in a Phase III study, the company reported, meeting the primary endpoint.

Specifically, the two drugs extended overall survival for patients with unresectable hepatocellular carcinoma who had not received prior systemic therapy and were not eligible for localized treatment.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 119,700+ biopharma pros reading Endpoints daily — and it's free.